Join us for a discussion this Thursday night:
- Major MCS trials- our journey so far
- Interview w/ DanGer Shock PI Prof. Jacob Moller
- How will DanGer impact your practice?
- Bleeding & vascular complications in a shock patient
- Future directions

Chuck Simonton…

Happy bday Matthew Schoenfeld ! I am blessed to have learned and gained your mentorship through the years 🫀 #funtimes Hackensack Meridian JSUMC. Best department EVER! #accfit American College of Cardiology Abbas Alshami Anton Mararenko Anas Alrefaee Palak R. Patel

They should have a ‘Hospital Politics’ course in med school

It was wonderful seeing so many #ACCMedStudents at #ACC24 - the community is strong going into Yr 4 and we are looking for the new team that will take it to the next level! If you’re interested in being a leadership member, please APPLY. The April 19th deadline is approaching. 🫀

I’m seeing some “free market” simps defending Nature’s 12k open access fees. Guess it’s time to bring this back around.

We often forget how many trainees get up at 5 am, day after day so they can get to the hospital at 630 or 7am

I greatly admire residents. The dedication and drive and committedness.

Interventional fellow running to a STEMI...

Totally fanboying meeting legends in Interventional Cardiology at #ACC24 American College of Cardiology #blessed Dr. Deepak L. Bhatt Akiko Maehara Emmanouil Brilakis Sunil V. Rao

#blessed for opportunity to present at #ACC24 complex cases performed at Hackensack Meridian JSUMC cardiology department. Thank you Madhav Upadhyaya for mentoring. Hackensack Meridian School of Medicine #ACCFIT #cardiology Matthew Schoenfeld Abbas Alshami Palak R. Patel Steven Imburgio

#DANGERSHOCK trial:
✅ Routine use of a microaxial flow pump + standard care in the tx of patients with STEMI-related #cardiogenicshock : ⬇️risk of death from any cause at 180 days 🆚 standard care alone.
➡️ incidence of Adv events were⬆️

#LBCT #ACC24

Be careful excluding the benefits of MCS in women after #DangerShock . Yes there are concern about vascular access but women much less likely to get life saving therapies due to bias. Lina Ya’Qoub MD and Alejandro Lemor MD, MS already showed this to us.

jacc.org/doi/10.1016/j.…

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today.

In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.

Some thoughts on this ground breaking trial:

ULTIMATE DAPT trial showed in pts with ACS treated with PCI, ticagrelor monotherapy btw 1 and 12 months decreased clinically-relevant and major bleeding, had similar protection from MACCE vs DAPT (ticagrelor + aspirin).

#blessed for the opportunity to engage in moderated discussion on gender disparities in STEMI-CS #ACC24 #accfit . Thank you Matthew Schoenfeld & Navin Kapur for your guidance. Hackensack Meridian Abbas Alshami Hackensack Meridian School of Medicine Palak R. Patel Steven Imburgio

Congratulations to Dr. Jacob Møller & colleagues for today's #ACC24 Late-Breaker & simultaneous NEJM publication of DanGer Shock! What a win for the interventional community & our patients with AMI Cardiogenic Shock! nejm.org/doi/full/10.10…

#CardiogenicShock in #Pregnancy warrants attention
🏷️⬆️ morbidity & mortality
🏷️ ⬇️ fetal outcomes
🏷️ Sparse data

Moderated by Dharini Ramu Jason N. Katz
Great talks by Natalie Tapaskar Jessica Schultz Anju Bhardwaj MD FACC Indranee Rajapreyar #RajivGulati #ACC24
Shelley Hall Katherine Clark Godiksen

#SMARTTrial shows superiority of SEV over BEV for performance at 12mo. Landmark trial enrolls “astounding” # of women, panelists noting that these findings not only remarkable on their own but speak to the need to study disease states which disproportionately impact women. #ACC24

Ready for #ACC24 Abbas Alshami Anton Mararenko Palak R. Patel Gursharan Singh Samra Hackensack Meridian NJ Chapter of ACC Hackensack Meridian School of Medicine